LCCC 9818: STAGE IIB, STAGE IIIA/B STAGE IV BREAST CANCER

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定手术前化疗加赫赛汀治疗局部晚期或新诊断的转移性乳腺癌(已从乳腺扩散到身体其他部位的癌症)是否安全有效。具体地说，这项研究中的患者将接受化疗药物阿霉素和环磷酰胺(4AC)的治疗，然后是化疗药物紫杉醇和赫赛汀。将对以下方面进行评估：1)治疗的副作用；2)治疗后肿瘤的缩小或消失；3)治疗后进行保乳手术的可能性。这项研究的另一个目的是确定对这种治疗的反应是否会导致更长的生存期。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if treatment of locally advanced or newly diagnosed metastatic breast cancer (cancer which has spread from the breast to other areas of the body) with chemotherapy plus Herceptin before surgery is safe and effective. Specifically, patients in this study will be treated with the chemotherapy drugs doxorubicin and cyclophosphamide (4AC) followed by the chemotherapy drug paclitaxel with Herceptin. The following will be evaluated: 1)the side effects of the therapy 2) the shrinkage or disappearance of the tumor from this therapy and 3) the possibility of performing breast-sparing surgery after this therapy. An additional purpose of this study is to determine whether response to this therapy results in longer survival.